{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/opioid-dependence/prescribing-information/buprenorphine/","result":{"pageContext":{"chapter":{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine","depth":2,"htmlHeader":"<!-- begin field 42a942d5-c2fc-4684-bc6b-a74d0097dce0 --><h2>Buprenorphine</h2><!-- end field 42a942d5-c2fc-4684-bc6b-a74d0097dce0 -->","summary":"","htmlStringContent":"<!-- begin item aaf1b1fa-1400-428e-b4cc-a74d0097dbfa --><!-- end item aaf1b1fa-1400-428e-b4cc-a74d0097dbfa -->","topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","lastRevised":"Last revised in October 2020","chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","fullItemName":"Management","slug":"management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8e178126-79a2-5aab-982f-ee57fbe89584","slug":"general-information","fullItemName":"General information","depth":3,"htmlHeader":"<!-- begin field 0cb0fa51-78bf-4afc-b071-a75c00b11f80 --><h3>General information on buprenorphine</h3><!-- end field 0cb0fa51-78bf-4afc-b071-a75c00b11f80 -->","summary":"","htmlStringContent":"<!-- begin item c252d2b7-6372-4a3a-bf38-a75c00b11cac --><!-- begin field 1f960072-8ff5-4510-8f16-a75c00b11f80 --><ul><li><strong>Buprenorphine is a semi-synthetic opioid with partial agonist properties, and it also has antagonist properties. </strong><ul><li>High doses of buprenorphine produce a less sedating effect than high doses of heroin, methadone, or morphine, and less respiratory depression.</li><li>At doses of more than 8 mg, buprenorphine blocks the effects of additional opioid use by preventing occupation of opioid receptors.</li><li>It is difficult to estimate equivalence between methadone and buprenorphine because there is not a linear relationship — buprenorphine 12–16 mg is approximately as effective as methadone 50–80 mg in reducing heroin use and maintaining people in treatment. It is difficult to compare doses above methadone 80 mg and above buprenorphine 16 mg because of their different effects.</li></ul></li><li><strong>Buprenorphine sublingual tablets </strong>are licensed for management of drug dependence — it is available in 400 microgram, 2 mg, and 8 mg formulations.<ul><li>Generic buprenorphine, Subutex and Suboxone (which contains the opioid antagonist naloxone in a combined sublingual tablet [buprenorphine: naloxone in a ratio of 4:1)] are licensed for the treatment of opioid dependence. <ul><li>Temgesic sublingual tablets and buprenorphine patches (Bu Trans, Transtec) are not licensed for the management of opioid dependence, do not contain the correct patient information leaflet, and should not be used for this purpose.</li></ul></li><li>Buprenorphine is inactivated by gastric acid and has a high first-pass metabolism. It is therefore available as sublingual tablets. </li></ul></li><li><strong>Buprenorphine prolonged-release injection</strong> (Buvidal) is licensed for treating opioid dependence within a framework of medical, social and psychological treatment in people aged 16 years and over. <ul><li>It is administered as a weekly injection (8 mg, 16 mg, 24 mg, or 32 mg) or monthly injection (64 mg, 96 mg, or 128 mg) by a healthcare professional and does not need daily supervised use.</li></ul></li><li><strong>Buprenorphine reaches </strong>peak concentration 90–150 minutes after sublingual administration. <ul><li>The time to peak clinical effect is 1–4 hours after the dose. </li><li>Buprenorphine's duration of action is related to dose:<ul><li>Low doses (2–4 mg) exert clinical effects for up to 12 hours.</li><li>Higher doses (16–32 mg) can exert clinical effects for up to 48–72 hours.</li></ul></li><li>Precipitated withdrawal can occur in someone commencing buprenorphine who has used heroin (within 8 hours) or methadone (within 24 hours). It typically occurs 1–3 hours after the first buprenorphine dose and peaks over the first 3–6 hours before subsiding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Ford et al, 2011</a>]</p><!-- end field 1f960072-8ff5-4510-8f16-a75c00b11f80 --><!-- end item c252d2b7-6372-4a3a-bf38-a75c00b11cac -->","subChapters":[]},{"id":"fc2c8157-fbbd-585e-9a91-ae9de8ed609c","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field b11d6385-1632-4d1e-9d7d-a74d00987fba --><h3>Maintenance treatment with buprenorphine</h3><!-- end field b11d6385-1632-4d1e-9d7d-a74d00987fba -->","summary":"","htmlStringContent":"<!-- begin item a7161566-9fb2-40b8-88ff-a74d00987eb6 --><!-- begin field 0858741e-2825-4d1f-abf4-a74d00987fba --><ul><li><strong>When switching from heroin:</strong><ul><li>Administer the first dose of buprenorphine when the person is exhibiting signs of withdrawal. </li><li>If withdrawal is difficult for the person to tolerate, delay the first dose of buprenorphine until 6–12 hours after the last dose of heroin. </li><li>Start on a low dose and titrate rapidly — rapid titration is essential to prevent drop out. <ul><li>A cautious approach is to initiate treatment with 4 mg on day one, then 8–16 mg on day two and thereafter.</li><li>Experienced and competent clinicians may increase the starting dose to 8 mg on day one and 16 mg on day two and thereafter increase the dose more slowly if necessary.</li><li>Dividing the daily dose may be useful as it may reduce precipitated withdrawal.</li><li>Review the person frequently during dose titration.</li><li><strong>Note:</strong> the maximum licensed starting dose recommended by the manufacturer is buprenorphine 4 mg.</li></ul></li></ul></li><li><strong>When switching from methadone</strong>, reduce the risk of withdrawal occurring by: <ul><li>Delaying the first dose of buprenorphine until the person is experiencing symptoms of opioid withdrawal (typically 24–36 hours after the last methadone dose).</li><li>Reducing the dose of methadone to 30 mg/day or less — this can be done by reducing the dose by 5 mg every 1–2 weeks until this goal is reached.</li></ul></li><li><strong>If the person experiences severe precipitated withdrawal symptoms on switching to buprenorphine:</strong><ul><li>Symptomatic treatment such as lofexidine an alpha-2 adrenergic agonist, can help with the unpleasant effects of the precipitated withdrawal (400 micrograms four times a day for 1–2 days).</li><li>Advise the person that 'on top' use of heroin will not help with withdrawal symptoms and may increase the risk of precipitated withdrawal because of the partial agonist properties of buprenorphine.</li></ul></li><li>When titrating the dose take into account the difficulties in prescribing for opiate-dependent people who use drugs — there are three competing pressures: <ul><li>To minimise the risk of overdosing, or precipitating withdrawal.</li><li>To respond rapidly to the person's perceived needs for treatment, manage symptoms of withdrawal, minimise distress, engage them in treatment and prevent any further harms from illicit drug misuse.</li><li>To avoid any unnecessary delays in achieving an effective substitution dose to stabilise the patient.</li></ul></li><li>The daily maintenance dose of buprenorphine is usually in the range 12–16 mg, although some people will need up to 32 mg. <ul><li>Prescribe buprenorphine initially for daily use — alternate-day dosing may be suitable for some people once treatment has stabilised. </li></ul></li><li>Review the person at every contact, and at least 3-monthly, to review care plans and goals, and to check for injecting sites.<ul><li>If the person is continuing to use illicit opioids there should be a low threshold for increasing the dose of buprenorphine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Ford et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Ford, Personal Communication, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">ABPI, 2019a</a>]</p><!-- end field 0858741e-2825-4d1f-abf4-a74d00987fba --><!-- end item a7161566-9fb2-40b8-88ff-a74d00987eb6 -->","subChapters":[]},{"id":"3379bee7-2223-517d-8a3a-ff4a420a74b8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8f9f2ae7-fdc5-48bd-8e85-a74d0098bbc6 --><h3>Contraindications and cautions</h3><!-- end field 8f9f2ae7-fdc5-48bd-8e85-a74d0098bbc6 -->","summary":"","htmlStringContent":"<!-- begin item c308b79d-122c-412a-86e8-a74d0098bad7 --><!-- begin field d3dd5020-3e68-4d23-b31a-a74d0098bbc6 --><ul><li><strong>Do not prescribe buprenorphine to people aged under 16 years (except on the advice of a specialist), or those with: </strong><ul><li>Allergy or proven intolerance to either methadone or buprenorphine.</li><li>Severe hepatic insufficiency.</li><li>Medical conditions, such as:<ul><li>Recent head injury.</li><li>Acute abdominal condition.</li><li>Severe respiratory insufficiency.</li><li>Acute alcoholism or delirium tremens.</li></ul></li><li>Severe mental illness with limited capacity to provide informed consent.</li><li>Non-opioid dependence.  </li></ul></li><li>Buprenorphine should be used with caution in people with:<ul><li>Renal insufficiency.</li><li>Respiratory disease, as there may be an increased risk of respiratory depression with buprenorphine (although less than with other opioids).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field d3dd5020-3e68-4d23-b31a-a74d0098bbc6 --><!-- end item c308b79d-122c-412a-86e8-a74d0098bad7 -->","subChapters":[]},{"id":"af12e079-27c3-56d2-8201-0d3a4e441917","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e54872cb-958f-4cdf-8c59-a74d0098da29 --><h3>Adverse effects</h3><!-- end field e54872cb-958f-4cdf-8c59-a74d0098da29 -->","summary":"","htmlStringContent":"<!-- begin item b3dcc178-f340-4f71-97dc-a74d0098d8d4 --><!-- begin field 036349f2-b101-4afe-b3c5-a74d0098da29 --><ul><li><strong>Common or very common adverse effects of buprenorphine include:</strong><ul><li>Anxiety, nervousness.</li><li>Back pain, chills, sweating.</li><li>Constipation, diarrhoea, nausea, vomiting.</li><li>Insomnia, dizziness, drowsiness, headache. </li><li>ECG abnormalities.</li><li>Syncope, orthostatic hypotension. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 036349f2-b101-4afe-b3c5-a74d0098da29 --><!-- end item b3dcc178-f340-4f71-97dc-a74d0098d8d4 -->","subChapters":[]},{"id":"6bc2d739-32d9-54d2-b7a4-2298f612f448","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ef9549e9-0890-4e9d-99fc-a74d0098ac82 --><h3>Drugs interactions</h3><!-- end field ef9549e9-0890-4e9d-99fc-a74d0098ac82 -->","summary":"","htmlStringContent":"<!-- begin item a25f1abc-ff00-40d5-892c-a74d0098ab96 --><!-- begin field cae62675-ed41-4c89-a525-a74d0098ac82 --><ul><li>Buprenorphine is extensively metabolized by the liver via the cytochrome P450 system, and blood levels can be affected by the concurrent use of drugs that either inhibit or induce liver enzymes. However, buprenorphine is a weaker inhibitor of cytochrome 3A4 in contrast to methadone, which is a strong inhibitor, and so may be preferred to methadone in some instances. </li><li><strong>Drugs that may increase blood levels of buprenorphine include:</strong><ul><li>Antibiotics — for example, erythromycin.</li><li>Azole antifungals — for example, ketoconazole or itraconazole.</li><li>Protease inhibitors — for example, ritonavir, indinavir, nelfinavir and saquinavir.  </li></ul></li><li><strong>Drugs that may decrease blood levels of buprenorphine include:</strong><ul><li>Antiepileptics — for example, phenobarbital, phenytoin, carbamazepine.</li></ul></li><li><strong>Respiratory depressants</strong> — for example alcohol, benzodiazepines, newer hypnotics (z-drugs), other sedatives, or tricyclic antidepressants. Concurrent use (especially on initiation of treatment) increases the risk of respiratory depression.</li><li>Any dose adjustments made for buprenorphine, because of concomitant medication should be reassessed on stopping this medication.</li><li><strong>Serotonergic agents</strong> — concurrent use of buprenorphine with other serotonergic agents, such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), or serotonin noradrenaline reuptake inhibitors (SNRIs), may result in serotonin syndrome.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Ford et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">ABPI, 2020</a>]</p><!-- end field cae62675-ed41-4c89-a525-a74d0098ac82 --><!-- end item a25f1abc-ff00-40d5-892c-a74d0098ab96 -->","subChapters":[]},{"id":"654945f2-d367-5d59-b67c-c935d6d98206","slug":"switching-from-buprenorphine-to-methadone","fullItemName":"Switching from buprenorphine to methadone","depth":3,"htmlHeader":"<!-- begin field 47294a82-4ff1-4dfe-bbe1-a75c008666b3 --><h3>How should I switch someone on buprenorphine maintenance to methadone maintenance?</h3><!-- end field 47294a82-4ff1-4dfe-bbe1-a75c008666b3 -->","summary":"","htmlStringContent":"<!-- begin item ccafbf2a-e0b3-4313-ab04-a75c008666ce --><!-- begin field 0c0bd94e-ecbb-4597-b646-a75c008666b3 --><ul><li><strong>Discuss with people that they may need to transfer from buprenorphine to methadone if they:</strong><ul><li>Have an inadequate treatment response.</li><li>Experience intolerable adverse effects.</li><li>Need other opioids for pain control.</li><li>Move to an area where buprenorphine is not used.</li></ul></li><li><strong>If a person is stable on buprenorphine, methadone can be commenced 24 hours after the last dose, at an initial daily dose of up to 30 mg</strong>. Always be aware of the risk of overdose if the higher starting doses are used especially if there is uncertainty about the reliability of the reported dose or if the person who uses drugs may be using 'on top'.</li><li>Titrate methadone according to the person's response, taking into account the long half-life and the residual partial antagonist action of buprenorphine, which may persist for several days. Proposed starting doses for switching from buprenorphine to methadone:<ul><li>Buprenorphine dose > 8 mg — methadone 30 mg.</li><li>Buprenorphine dose 4 mg — methadone 20 mg.</li><li>Buprenorphine dose 2 mg — methadone 10 mg.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">Ford, Personal Communication, 2014</a>]</p><!-- end field 0c0bd94e-ecbb-4597-b646-a75c008666b3 --><!-- end item ccafbf2a-e0b3-4313-ab04-a75c008666ce -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}